Euroopa Liit - eesti - EMA (European Medicines Agency)

teva b.v. - lamivudiin - b-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - lamivudine teva on näidustatud ravi kroonilise b-hepatiidi täiskasvanutel:kompenseeritud maksahaigus koos tõendite aktiivse viiruse replikatsiooni, püsivalt suurenenud seerumi alaniini kontsentratsioon (alt) tase ja histoloogilise tõendeid aktiivne maksapõletik ja / või fibroos. algatamise lamivudine ravi tuleks kaaluda ainult juhul, kui kasutada alternatiivset viirusevastane esindaja suurem geneetiline barjäär ei ole kättesaadav või kui see on asjakohane (vt punkti 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Euroopa Liit - eesti - EMA (European Medicines Agency)

krka, d.d., novo mesto - irbesartaanvesinikkloriid - hüpertensioon - reniini-angiotensiini süsteemi toimivad ained - essentsiaalse hüpertensiooni ravi. ravi neeruhaigusega patsientidel, kellel on hüpertensioon ja 2. tüüpi suhkurtõve osana hüperaktiivsuse vastased ravimi raviskeemi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - olansapiin - schizophrenia; bipolar disorder - psühhoeptikumid - kaetud tabletsadultsolanzapine on näidustatud skisofreenia ravi. olansapiin on efektiivne, säilitades kliinilist paranemist ajal jätkamine ravi patsientidel, kes on näidanud, esialgne ravi vastuseks. olansapiin on näidustatud ravi mõõduka kuni raske maniakaalse episoodi. patsientidel, kelle maniakaalne episood on vastanud, et olansapiin-ravi, olansapiin on näidustatud kordumise ennetamiseks patsientidel, kellel on bipolaarne häire. injectionadultszyprexa pulber süstelahus on näidustatud kiire kontrolli agitatsioon ja häiritud käitumist patsientidel skisofreenia või maniakaalne episood, kui suukaudne ravi ei ole sobiv. ravi zyprexa pulber süstelahus tuleb katkestada ja kasutada suukaudse olansapiini tuleb alustada nii kiiresti kui see on kliiniliselt asjakohane.

Euroopa Liit - eesti - EMA (European Medicines Agency)

n.v. organon - asenapine (as maleate)  - bipolaarne häire - psühhoeptikumid - sycrest on näidustatud täiskasvanutele i tüüpi bipolaarse häirega seotud mõõdukate või raskete maniakaalsete episoodide raviks.

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+5mg 84tk; 40mg+5mg 90tk; 40mg+5mg 14tk; 40mg+5mg 60tk; 40mg+5mg 30tk; 40mg+5mg 56tk; 40mg+5mg 98tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 20mg+5mg 98tk; 20mg+5mg 84tk; 20mg+5mg 60tk; 20mg+5mg 14tk; 20mg+5mg 30tk; 20mg+5mg 56tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+10mg 28tk; 40mg+10mg 30tk; 40mg+10mg 98tk; 40mg+10mg 84tk; 40mg+10mg 14tk; 40mg+10mg 56tk; 40mg+10mg 90tk; 40mg+10mg 60tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

krka - olansapiin - schizophrenia; bipolar disorder - psühhoeptikumid - olansapiin on näidustatud skisofreenia raviks. olansapiin on efektiivne, säilitades kliinilist paranemist ajal jätkamine ravi patsientidel, kes on näidanud, esialgne ravi vastuseks. olansapiin on näidustatud ravi mõõduka kuni raske maniakaalse episoodi. patsientidel, kelle maniakaalne episood on vastanud, et olansapiin-ravi, olansapiin on näidustatud kordumise ennetamiseks patsientidel, kellel on bipolaarne häire.